Does ASC4FIRST data justify the use of first-line asciminib for all newly diagnosed CML over other TKIs, considering that the MMR difference was not significantly different, and post-progression survival data is not yet mature?  

Ideally, every patient gets the newest and greatest, but the elephant in the room is asciminib’s $145,000 per year cost compared to imatinib’s $600.

Although an excellent addition to the treatment armamentarium given its excellent tolerability, I do not think the data justifies the use of asciminib for all newly diagnosed CP CML patients. Although MMR and deeper responses providing the opportunity for TFR are a key goal for many patients, overal...

The difference in MMR was indeed statistically significant, so I would consider it for all my patients. We do not expect survival benefits since we already achieved near-normal life expectancy with imatinib. The goals of developing new and better therapies are to improve on other goals, such as havi...

With longer follow-up, the advantages in response with asciminib compared to imatinib and compared to ‘all other TKI choices (including imatinib and second generation)’ were both significant; while not powered (difficult to impossible given the numbers of patients needed) to show statist...